ANN ARBOR, Mich. — A study led by the University of Michigan Cardiovascular Center shows being a woman may not increase your risk of dying from treatment for a severe heart attack.
U-M researchers and colleagues in the Michigan Cardiovascular Co…
ANN ARBOR, Mich. — Are some children genetically tuned to be overweight, or is lifestyle to blame for childhood obesity?
Check-ups of 1,003 Michigan 6th graders in a school-based health program showed children who are obese were more likely to c…
Alefacept, a specially designed molecule that blocks a specific immune-system reaction involved in the painful skin condition psoriasis, was approved for marketing today under the name Amevive. Biogen, Inc. of Cambridge, Mass., will market the drug. Alefacept traces its roots to research done at the U-M in the mid-1990s by a team led by former dermatology faculty member Kevin D. Cooper, M.D. The University and Biogen share the patent on the engineered molecule with Cooper, who is now chair of dermatology at Case Western Reserve University in Cleveland.